Physician Resources
Recently Added |view more
News
ENDING THE RELIANCE ON BCG.
A Phase III clinical trial for bladder cancer
The Phase III randomized trial compares Bacillus Calmette-Guerin (BCG) immunotherapy, the standard-of-care intravesical treatment for high grade non-muscle invasive bladder cancer, versus intravesical Docetaxel and Gemcitabine treatment in BCG naïve patients.
Document
DEPARTMENT OF HEMATOLOGY/ONCOLOGY THORACIC CANCERS CLINICAL TRIALS
For general questions about clinical trials, call 215-214-1515 or visit FoxChase.org/ClinicalTrials.
News
The study is a phase one, single-site, dose-escalation study for patients with myeloproliferative neoplasms unresponsive to any JAK2 inhibitor. It combines two oral medications, Pacritinib and Talazoparib, and is for transplant-ineligible patients.
News
Thomas J. Galloway, MD, Chief of the Division of Head and Neck Radiation Oncology at Fox Chase Cancer Center, was today named a Fellow of the American Society for Radiation Oncology (ASTRO) at its 66th Annual Meeting in Washington, D.C.
Document
Thoracic Malignancies: A Review of the Latest Evidence - AGENDA
Presented by Fox Chase Cancer Center, the Temple Lung Center, and the Temple Health Office for Continuing Medical Education
News
Using CT-guided online adaptive radiation therapy (ART) for patients with liver tumors has proven to be an effective approach, according to findings presented today by Fox Chase Cancer Center researchers at the American Society for Radiation ...
News
Eric Horwitz, MD, FABS, FASTRO, Chair of the Department of Radiation Oncology at Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University, was elected to the Executive Committee of the Society of Chairs of Academic ...
News
Online adaptive radiation therapy (ART) delivered radiation more effectively than conventional radiation therapy in nearly half of patients, while also helping to decrease radiation dose to the esophagus in a majority of patients with ...